Multiple Myeloma News

I didn't realize that former NBA star, Flynn Robinson, had multiple myeloma. Good Medical Daily article discussing African American myeloma related issues...

noreply@blogger.com (Pat and Pattie Killingsworth) — Sat, 25 May 2013 15:48:00 +0000

Former Laker Flynn Robinson Dies at 72, Battling Multiple Myeloma Cancer

Former Laker Flynn Robinson dies at 72, after fighting the uncommon cancer multiple myeloma for two years. Fans mourn Robinson, who helped lead the Los Angeles Lakers to their first NBA championship.

Unusual case blaming multiple myeloma on chemical exposure...

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 24 May 2013 19:31:00 +0000

Benzene suit against 18 companies slated for trial in summer of 2014

Millennium's MLN9708 is most likely the next novel therapy agent to be approved by the FDA, hopefully sometime next year. This study involves patients that are newly diagnosed and not transplant eligible:

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 24 May 2013 03:26:00 +0000

Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma

-- First oral proteasome inhibitor investigated in newly diagnosed patients

Up to now, secondary cancer concerns surrounded Revlimid when used as maintenance following high dose melphalan prior to stem cell transplants. But thalidomide is still commonly used in Canada and Europe. So Canadian officials have been monitoring thalidomide and discovered a small but significant secondary cancer risk:

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 24 May 2013 03:12:00 +0000

Cancer treatment could cause other cancers

Abstract that briefly covers amyloidosis basics:

noreply@blogger.com (Pat and Pattie Killingsworth) — Tue, 21 May 2013 23:34:00 +0000

Systemic light chain amyloidosis: an update for treating physicians

This is intriguing! Apparently the new therapy agent, melflufen, targets over-expressed enymes and its active metabolite is entrapped at high concentrations within the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease...

noreply@blogger.com (Pat and Pattie Killingsworth) — Tue, 21 May 2013 18:51:00 +0000

Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

Read more here: http://www.sacbee.com/2013/05/21/5436160/oncopeptides-secures-venture-funding.html#storylink=cpy

I'm not familiar with NORD. The more working on developing improved therapies, the better!

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 17 May 2013 15:41:00 +0000

NO LINK AVAILABLE

NORD honors Onyx Pharmaceuticals for development of Kyprolis

Last night in Washington, DC, at its annual gala, the National Organization for Rare Disorders (NORD) -- of which the IMF is a member organization -- recognized Onyx Pharmaceuticals for the development and approval of carfilzomib (Kyprolis) for the treatment of progressive forms of multiple myeloma.

Amyloidosis related presentation important for our readers interested in amyloidosis

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 17 May 2013 01:27:00 +0000

Alnylam Pharmaceuticals' CEO Presents at 2013 Bank of America Merrill Lynch Health Care Conference (Transcript)

Onyx Pharmaceuticals is featuring a few more Kyprolis study results at ASCO than Celgene, but many are for blood cancers besides multiple myeloma...

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 17 May 2013 01:10:00 +0000

NO LINK AVAILABLE

Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting

SOUTH SAN FRANCISCO, CA--(Marketwired - May 15, 2013) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection, and Stivarga® (regorafenib) tablets across a range of cancers. These presentations will take place at the 49th American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, 2013, in Chicago, IL.

"The data being presented at ASCO add to the depth of our understanding of how these medicines work across tumor types and treatment settings," said Pablo Cagnoni, M.D., Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."
Nexavar® (sorafenib) tablets

Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The Phase 3 DECISION trial

Dr. Marcia Brose, University of Pennsylvania Health System, United States
Sunday, June 2, 2013
Oral Presentation: 3:20 - 3:35 p.m., N Hall B1
Plenary Session - Special Sessions, Core Sessions
Abstract # 4

Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in > 3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction

Dr. Jorge Marrero, University of Michigan, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Noncolorectal) Cancer
Abstract # 4126

Kyprolis® (carfilzomib) for Injection
Final results from the Phase 1b/2 study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma

Dr. Michael Wang, MD Anderson Cancer Center, United States
Monday, June 3, 2013
Poster viewing: 1:15 - 5:15 p.m., E450b
Poster discussion: 4:45 - 5:45 p.m., E354b
Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster #9
Abstract # 8529

Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a Phase (Ph) 1/2 trial

Dr. Cyrille Touzeau, University of Nantes, France
Monday, June 3, 2013
Oral Presentation: 9:15 - 9:30 a.m., E Arie Crown Theater
Oral abstract session - Myeloma
Abstract # 8513

Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM)

Dr. Shebli Atrash, University of Arkansas for Medical Sciences, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Lymphoma and Plasma Cell Disorders
Abstract # 8595

Results of a Phase 1/2 study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)

Dr. James R. Berenson, Institute for Myeloma & Bone Cancer Research, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Lymphoma and Plasma Cell Disorders
Abstract # 8599

Results of a Phase 1 trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)

Dr. Jennifer Ann Woyach, Ohio State University, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Leukemia, Myelodysplasia, and Transplantation
Abstract # 7077

Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up

Dr. Andrzej J. Jakubowiak, University of Chicago, United States
Monday, June 3, 2013
Poster viewing: 1:15 - 5:15 p.m., E450b
Poster discussion: 4:45 - 5:45 p.m., E354b
Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster #23
Abstract # 8543

Stivarga® (regorafenib) tablets
Mutational analysis of plasma DNA from patients (pts) in the Phase 3 GRID study of regorafenib (REG) vs placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes

Dr. George Demetri, Dana-Farber Cancer Institute, United States
Monday, June 3, 2013
Oral Presentation: 3:45 - 4:00 p.m., S100bc
Oral abstract session - Sarcoma
Abstract # 10503

Results from a Phase 3 trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): subgroup analysis of outcomes based on pretreatment characteristics

Dr. Heikki Joensuu, Helsinki University Central Hospital, Finland
Saturday, June 1, 2013
Poster viewing: 1:15 - 5:00 p.m., S Hall A2
General poster session - Sarcoma
Abstract # 10551

Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: an ongoing randomized, double-blind, Phase 3 trial

Dr. Ann-Lii Cheng, National Taiwan University Hospital, Taipei
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Noncolorectal) Cancer
Abstract # TPS4163 (Trials in Progress)

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the Phase 3 CORRECT study

Dr. Axel Grothey, Mayo Clinic, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Colorectal) Cancer
Abstract # 3637

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): analysis of age subgroups in the Phase 3 CORRECT trial

Dr. Eric van Cutsem, University Hospital Leuven in Gasthuisberg, Belgium
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Colorectal) Cancer
Abstract # 3636

Analysis of plasma protein biomarkers from the CORRECT Phase 3 study of regorafenib for metastatic colorectal cancer

Dr. Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, United States
Tuesday, June 4, 2013
Poster viewing: 8:00 - 12:00 p.m., S405
Poster discussion: 11:30 - 12:30 p.m., S406
Poster discussion session - Gastrointestinal (Colorectal) Cancer, Poster #6
Abstract # 3514

I was surprised by how few presentations were being made at ASCO in June on Celgene's behalf. The warnings were three times as long as the presentation part of the news release...

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 17 May 2013 00:58:00 +0000

NO LINK AVAILABLE

MULTIPLE PRESENTATIONS AND POSTERS EVALUATING CELGENE PRODUCTS TO BE HIGHLIGHTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2013 ANNUAL MEETING

Clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in approximately 30 posters and presentations evaluating Celgene products in a range ofcancers including pancreatic cancer, multiple myeloma, myelodysplastic syndromes, and non-Hodgkin’s lymphomas at the American Society of Clinical Oncology 2013 Annual Meeting being held at the McCormick Place in Chicago, IL, from May 31 – June 4, 2013. As part of this collection of abstracts, there are multiple oral presentations, including:

*Times listed are Central Daylight Time

Pancreatic Cancer:

Abstract #4005 – Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates (Von Hoff, et al.) – Monday, June 3, 11:15 a.m., E Hall D1

Multiple Myeloma:

Abstract #8509 – Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients (Boccadoro ) – Monday, June 3, 8 a.m., E Arie Crown Theater

Abstract #8510 - A phase 3, multicenter, randomized, open-label study of pomalidomide (POM) + low-dose dexamethasone (LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) (San Miguel) – Monday, June 3, 8:15 a.m., E Arie Crown Theater

Myelodysplastic Syndromes:

Abstract #7002 – A Randomized study of lenalidomide (LEN) +/- erythropoietin (EPO) in RBC transfusion dependent (TD) lower risk myelodysplastic (MDS) without del 5q resistant to EPO– GFM. LenEpo 2008 study (Toma, et al) – Tuesday, June 4, 8:15 a.m., E354b

My last post showed you a snapshot from an untrained writer's point of view. This link takes you to a general article about multiple myeloma and new therapies from a pharmacists point of view. Interesting. Cold, matter of fact. A stark contrast from my last post...

noreply@blogger.com (Pat and Pattie Killingsworth) — Wed, 15 May 2013 15:43:00 +0000

Pharmacist to Pharmacist
Multiple Myeloma: Advances in Treatment Bring Hope

I run across local human interest stories about multiple myeloma patients daily. I usually don't share them with you here. But this one is touching and sheds some light on how our cancer is percieved by the public. Worth a look!

noreply@blogger.com (Pat and Pattie Killingsworth) — Wed, 15 May 2013 15:34:00 +0000

Couple remains hopeful after rare cancer diagnosis

Its not a secret, but money is needed in order to follow-up on all of these new, exciting myeloma therapy ideas. I have written about Senesco Technologies' promising new drug, SNS01-T, a number of times. So this is good news! Looks like Senesco has enough money to keep working on it...

noreply@blogger.com (Pat and Pattie Killingsworth) — Fri, 10 May 2013 19:18:00 +0000

Senesco Announces $1.255 Million Equity Financing

Read more here: http://www.heraldonline.com/2013/05/09/4848642/senesco-announces-1255-million.html#storylink=cpy

This type of fundraising is expensive. But both the MMRF and IMF run similar events so it must work...

noreply@blogger.com (Pat and Pattie Killingsworth) — Thu, 09 May 2013 19:13:00 +0000

Wall Street Journal

Over 700 Attend Annual Multiple Myeloma Research Foundation (MMRF) Laugh for Life: New York to Raise Critical Funds for Cancer Research

I'm not sure I've ever followed a drug company that has issued as many press releases as Patrys Limited. Any - and I mean ANY - hint of good news and releases are issued with great fanfare. So while this is good news, it is way too early to be doing cartwheels. Patrys must really need to raise money...

noreply@blogger.com (Pat and Pattie Killingsworth) — Wed, 08 May 2013 16:08:00 +0000

Patrys Limited : May 8, 2013 - PAT-SM6 Kills Human Multiple Myeloma Cells

Despite excitement over Kyprolis, this Onyx financial report seems to indicate that sales from the new agent have only begun to trickle-in...

noreply@blogger.com (Pat and Pattie Killingsworth) — Tue, 07 May 2013 22:05:00 +0000

NO LINK AVAILABLE

Onyx Pharmaceuticals Reports First Quarter 2013 Financial Results

Total Revenues Double to $145 Million; Kyprolis(R) Net Sales of $64 Million

SOUTH SAN FRANCISCO, CA--(Marketwired - May 07, 2013) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the first quarter 2013 and provided a business update on Kyprolis® (carfilzomib) for Injection, Nexavar® (sorafenib) tablets and Stivarga® (regorafenib) tablets.

"We began 2013 with a broad portfolio of products driving growth and momentum across our business," said N. Anthony Coles, M.D., chairman and chief executive officer of Onyx. "In our proteasome inhibitor franchise, we continue to execute a successful launch of Kyprolis in the United States, adding select capabilities internationally, and investing in a broad Phase 3 clinical development program across all lines of therapy. Our global kinase inhibitor business, with Nexavar as the cornerstone, and Bayer's Stivarga, continues to provide important contributions enabling our strategic investments."

Onyx reported total revenue of $145.5 million for the first quarter 2013. Onyx reported non-GAAP net loss of $13.7 million, or $0.19 per diluted share, for the first quarter 2013. On a GAAP basis, Onyx reported net loss of $33.7 million, or $0.47 per diluted share, for the first quarter 2013. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Financial Measures."

Revenue
For the first quarter of 2013, Onyx reported total revenue of $145.5 million, as compared to total revenue of $72.0 million for the comparable period in 2012.

Revenue from the Nexavar collaboration agreement with Bayer for the first quarter of 2013 was $70.3 million, as compared to $72.0 million for the comparable period in 2012. The decrease in revenue from collaboration is primarily due to inventory reductions of specialized oncology pharmacies in the United States and lower sales in Europe which were partially offset by growth in the Asia-Pacific region and improved commercial margin in the business.
Kyprolis net sales for the first quarter of 2013 were $64.0 million, including a favorable gross-to-net accrual adjustment of $5.9 million. Demand sales were $58.1 million, representing orders shipped to and received by end customers such as physician offices and hospitals. In addition, Onyx recorded deferred revenue of $9.3 million as of March 31, 2013, representing Kyprolis inventory at distributors which has not yet shipped to physician offices and hospitals.
Stivarga royalty revenue was $9.2 million for the first quarter of 2013. Onyx receives a 20% royalty on global net sales of Stivarga in jurisdictions that have received commercial marketing approval. Stivarga is a Bayer compound developed by Bayer and jointly promoted by Bayer and Onyx in the United States.

Operating Expenses
Non-GAAP cost of goods sold was $1.9 million for the first quarter of 2013. Cost of goods sold related to sales of Kyprolis is not representative of Onyx's future expectations of cost of goods sold because certain product costs associated with Kyprolis sales in the first quarter of 2013 were charged to research and development expense in periods prior to approval. On a GAAP basis, cost of goods sold was $2.0 million for the first quarter 2013.

Non-GAAP research and development expense was $88.8 million for the first quarter of 2013, compared to $78.7 million for the same period in 2012. Higher research and development expense between periods was primarily due to the global development of Kyprolis, particularly the ongoing Phase 3 ENDEAVOR trial and start-up activities associated with the front-line CLARION study, which was offset by lower Nexavar development expense. On a GAAP basis, research and development expense was $91.3 million for the first quarter 2013, compared to $80.7 million for the same period in 2012.

Non-GAAP selling, general and administrative expense was $66.5 million for the first quarter 2013, compared to $34.1 million for the same period in 2012. Higher selling, general and administrative expense between periods was primarily related to the increased headcount following the hiring of the field force associated with the commercial launch of Kyprolis in the United States. On a GAAP basis, selling, general and administrative expense was $72.5 million for the first quarter 2013, compared to $38.9 million for the same period in 2012.

Amortization expense for certain intangible assets was $5.2 million for the first quarter 2013, and reflects the amortization of a portion of the intangible asset, which was acquired in the 2009 acquisition of Proteolix, Inc.

Cash, Cash Equivalents and Marketable Securities
On March 31, 2013, cash, cash equivalents and current and non-current marketable securities were $738.9 million, compared to $492.8 million at December 31, 2012. The increase is primarily due to proceeds of approximately $352 million received from a public offering of 4.4 million shares of common stock, completed in January 2013.

Non-GAAP Financial Measures
This press release and the reconciliation table included herein includes the following non-GAAP financial measures: non-GAAP net income (loss), non-GAAP net income (loss) - diluted, non-GAAP net income (loss) per share, non-GAAP net income (loss) per share - diluted, non-GAAP cost of goods sold, non-GAAP research and development expense, non-GAAP selling, general and administrative expense and non-GAAP operating expenses. A description of the non-GAAP calculations and reconciliation to the comparable GAAP financial measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Financial Measures."

Onyx management uses these non-GAAP financial measures to monitor and evaluate our operating results and trends on an on-going basis, and internally for operating, budgeting and financial planning purposes. Onyx management believes the non-GAAP information is useful for investors by offering the ability to better identify trends in our business and better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expense that affect Onyx. These non-GAAP financial measures are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Financial Measures."

Non-GAAP operating expenses exclude contingent consideration expense (benefit), employee stock-based compensation expense, imputed interest related to the convertible senior notes due 2016 and amortization of certain intangible assets.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The Company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the Company's website at www.onyx.com.

But this one is newer: ENMD-2076. Only one previous posted link about this one...

noreply@blogger.com (Pat and Pattie Killingsworth) — Mon, 06 May 2013 21:30:00 +0000

Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076

Patent Covers Composition of Matter and Uses for Various Cancers

February 4th LINK:

http://www.myelomanews.com/2011/02/hot-off-presses-new-drug-enmd-2076.html

Read more here: http://www.sacbee.com/2013/05/06/5397583/patent-issued-in-china-for-entremeds.html#storylink=cpy

This Lund University sponsored press release ran on a number of mid-level science sites recently. I have run a half dozen links to articles about BI-505 over past six months...

noreply@blogger.com (Pat and Pattie Killingsworth) — Mon, 06 May 2013 21:22:00 +0000

Possible Treatment for Serious Blood Cancer

I participated in and wrote about this webcast earlier in the year. Dr. Anderson does an excellent job recapping news from ASH and explaining what is and why its important...

noreply@blogger.com (Pat and Pattie Killingsworth) — Sat, 04 May 2013 15:32:00 +0000

http://www.rmei.com/llsmyeloma
Online Virtual Lecture/Podcast Now Available!

Francine Gendron is the new Executive Director of Myeloma Canada

noreply@blogger.com (Pat and Pattie Killingsworth) — Sat, 04 May 2013 14:56:00 +0000

Myeloma Canada Announces Appointment of Executive Director

Comprehensive article about Millennium Pharmaceutical's re-launch of MyMultipleMyeloma.com

noreply@blogger.com (Pat and Pattie Killingsworth) — Thu, 02 May 2013 22:14:00 +0000

Millennium launches new blood cancer resource

Good news for some amyloidosis patients considering autologous stem cell transplants...

noreply@blogger.com (Pat and Pattie Killingsworth) — Thu, 02 May 2013 22:06:00 +0000

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center

This is important stuff. Definitive guidelines about what different bisphosphonates can and cannot do, when to use them and why...

noreply@blogger.com (Pat and Pattie Killingsworth) — Thu, 02 May 2013 19:23:00 +0000

Optimal use of bisphosphonates in patients with multiple myeloma

This isn't new news. But focus on Total Therapy makes a lot of sense. These patients are given a lot of chemotherapy that includes melphalan for high dose chemo and one or more IMiDs (Thalomid/Revlimid)

noreply@blogger.com (Pat and Pattie Killingsworth) — Thu, 02 May 2013 19:06:00 +0000

Secondary Cancer Risk Found With Multiple Myeloma Maintenance Therapies

This is big news for myeloma patients. I was on warfarin for almost six years. Here's hoping that Kcentra can help make us all safer!

noreply@blogger.com (Pat and Pattie Killingsworth) — Wed, 01 May 2013 03:55:00 +0000

FDA OKs Kcentra for Fast Fix of Coumadin Bleeds

By Chris Kaiser, Cardiology Editor, MedPage Today

Published: April 30, 2013